EIDD-2749

CAT: 0804-HY-146246-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-146246-01Size:5 mg
Selected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV) . EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses[1][2][3].
CAS Number
[1613589-24-4]
Product Name Alternative
4'-FlU; 4'-Fluorouridine
UNSPSC
12352005
Target
HCV; RSV; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/eidd-2749.html
Purity
99.86
Solubility
DMSO : 25 mg/mL (ultrasonic) |H2O : 10 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1NC(N([C@@H]2O[C@@](CO)(F)[C@@H](O)[C@H]2O)C=C1)=O
Molecular Formula
C9H11FN2O6
Molecular Weight
262.19
References & Citations
[1]Sourimant J, et al. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science. 2022 Jan 14;375 (6577) :161-167. |[2]Abas AH, et al. 4’-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review [version 1; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2022, 11:410. |[3]George R. Painter, et al. 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. Patent WO2019173602A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported